In addition, the levels of tumor-derived mutant KRAS DNA were highest in association with large EVs and sEVs early and with sEVs and soluble proteins late in disease progression, indicating that sEVs were the most enriched in tumor-derived DNA throughout disease progression [130]. This evidence concerns the gene KRAS and neoplasm.